Clinical trials of oncolytic virotherapy as a neoadjuvant
| Study title | Trial number | Completion date | Reference |
| Efficacy and safety of Talimogene Laherparepvec neoadjuvant treatment plus surgery versus surgery alone for melanoma | NCT02211131 | 22 April | 34 |
| A phase 1/2 study of Talimogene Laherparepvec in combination with neoadjuvant chemotherapy in triple-negative breast cancer NCT02779855 injected directly into the tumor during chemotherapy prior to surgery | NCT02779855 | 23 August | 37 |
| Biomarker analysis of neoadjuvant intralesional therapy in high-risk early melanoma Ph 2 Talimogene Laherparepvec | NCT04427306 | 24 May | 38 |
| Stage IIIB/C/D–IV M1a melanoma with injectable disease | NCT04330430 | 23 August | 39 |
| Neoadjuvant combination immunotherapy for stage III melanoma | NCT03842943 | 22 March | 40 |
| Phase II neoadjuvant trial of nivolumab in combination with HF10 oncolytic viral therapy in resectable stage IIIB, IIIC, IVM1a melanoma (Neo-NivoHF10) | NCT03259425 | 20 September | 41 |
| A phase IIa study of neoadjuvant JX-594 (thymidine kinase-deactivated vaccinia virus plus GM-CSF) administered by intravenous infusion or intratumoral injection followed by surgical resection in patients with metastatic colorectal tumors within the liver | NCT01329809 | 13 March | 43 |
| Phase I study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) and/or recombinant fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma scheduled for cystectomy | NCT00072137 | 10 November | 45 |
| Neoadjuvant intravesical NIS measles virus (MV-NIS) in patients undergoing cystectomy for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy | NCT03171493 | 22 December | 46 |
| Safety and effectiveness study of G207, a tumor-killing virus, in patients with recurrent brain cancer | NCT00028158 | 3 October |